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Gy/fraction, twice- daily to a total dose of 10-20 Gy (one 
week apart) according to the dose of the external beam 
radiotherapy. The total dose ranged from 76-84 Gy when 
transformed to EQD2 models. Patients were followed up by 
contrast-enhanced CT or MRI 4 weeks and then every 3 
months after the end of treatment. The primary end point 
was local tumor control. Secondary end points of the adverse 
events, distant metastases and progression-free survival were 
also included. 
 
Results: The first follow-up examination after 4 weeks 
revealed 10/11 coverage of all nodal metastases treated. 
There was no peri-interventional mortality or major 
complications. The mean follow-up period was 12.2 months 
(range 7–15 months). After a median follow up of three 
months, the median local tumor control was 90%. 2 out of 10 
patients (20%) showed local tumor progression 6 and 8 
months after brachytherapy. 2 patients (20%) who died of 
distant metastasis. The grade III-IV complications occurred in 
1 patient (10%). The mean progression-free interval was 13 
months (range 6–16 months).  
 
Conclusion: We consider that the interstitial brachytherapy 
technical will provide a relative high and accurate dose 
irradiation to bulky lymph node metastasis for improving the 
local tumor control in patients with different solid cancers. 
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Purpose or Objective: Commissioning of HDR brachytherapy 
treatment equipment is essential to avoid errors and assure 
quality. However, it is estimated that worldwide, less than 
one-quarter of centres undertake robust local commissioning 
tests at installation [1], important checks may be omitted 
[2], or systematic errors may remain [3]. The purpose of this 
work is to: (i) reinforce the need for local HDR commissioning 
and propose a list of recommended tests; (ii) publish results 
of the commissioning for a new-to-market HDR brachytherapy 
system from two centres. 
 
Material and Methods: A literature review was conducted on 
existing guidance for HDR system commissioning, HDR 
treatment errors and known factors affecting sub-optimal 
quality. The case for robust local commissioning of HDR 
equipment was assessed in terms of mitigating potential 
errors and improving quality of treatment delivery. A 
schedule of required commissioning tests was established and 
implemented at two centres, in England and Germany, for 
the commissioning of a new HDR brachytherapy treatment 
system, SagiNova (Eckert & Ziegler Bebig GmbH) with Co-60 
sources. 
 
Results: Evidence was found that errors do occur [4], 
particularly in the absence of robust commissioning and QC. 
There is little contemporary guidance for commissioning of 
HDR brachytherapy treatment equipment, which is required 
to build on the QC guidance in ESTRO Booklet No. 8 from 
2004. The table provides our proposal for efficient, robust, 
and easily implemented commissioning tests. For the 
SagiNova system, results from the two centres showed 
satisfactory performance in all tests. The mean error for 
source dwell positions in straight catheters was 0.5 mm (±0.5 
mm k=2) and in clinical treatment applicators was 0.6 mm 
(±1.0 mm k=2) compared to TPS planned positions. The ‘end 
to end’ system check with IPEM ‘BRAD’ system [5] had 
prescription point <0.4% (±2.5% k=2) and 97% gamma pass 
rate (3%, 2mm) compared to TPS calculations. By comparing 
results between centres a quality improvement was 
identified and implemented comprising an update of the 
dwell-position database at one centre. 
 
 
Conclusion: It is not sufficient to rely on type-testing by 
manufacturers and instead local commissioning must be 
implemented to assure quality and mitigate the risk of 
treatment errors in HDR brachytherapy. Suitable tests are not 
always performed and a schedule of minimum commissioning 
tests has been proposed. The first two installations of the 
new SagiNova HDR system demonstrated clinically acceptable 
results. An improvement of the source dwell database was 
identified, confirming the value of interdepartmental checks 
and robust commissioning. 
[1] Personal communication with HDR manufacturer,  
[2] Nisbet et al Radiother Oncol 106(sup 2):2013,  
[3] Palmer et al Br J Radiol 87(1041):2014,  
[4] ASAHI SHIMBUN 2014, AJ201312260063 
[5] Palmer et al Radiother Oncol 114(2):2015 
 
EP-1986  
New design of brachytherapy water phantom for absolute 
dosimetry 
V. Stserbakov
1North-Estonian Regional Hospital Cancer Center 




Purpose or Objective: To simplify technical design of 
brachytherapy water phantom for performing absolute 
dosimetry using standard instruments and equipment 
available in radiotherapy department. To perform absolute 
measurements for source-to-ionization chamber distance ~ 4 
cm. 
 
Material and Methods: CNMC WP-380 water tank used for 
locating ionization chamber and the holder of the radioactive 
source. To minimize dimensional correction factors for 
ionization chamber it was taken 0,125 cm3 PTW 31010 
ionization chamber. For reducing uncertainty of the source 
position inside mould probe we used “curved catheter” 
method in the design of the catheter holder to make an 
effect of “pressing down” the end part of cable to lower wall 
of the probe. Holder designed in this way that amount of 
other than water surrounding source material was maximally 
reduced. Source-to-ionization chamber distance was set by 
S940                                                                                                                                                  ESTRO 35 2016 
_____________________________________________________________________________________________________ 
using "head pin" device. Swinging of the pin like a swinging of 
the pendulum was used for identifying the contact of pin 
with ionization chamber surface. It helps to avoid specific 
challenges of other technical decisions for source-to-
ionization chamber distance setting. For pin swinging the 
water tank should be mounted on to wheeled stand. Final 
mechanical uncertainty for distance we estimate as ±0.15 
mm, which correspond to the inaccuracy in dose: ±0.8 %. 
GammaMed Plus remote afterloader with source Ir-192 HDR 
(diam. 0.9 mm) was used. Varian BrachyVision V10(TG-43) 




Figure: 1 – Ionization chamber; 2 - "Head pin" positioning 
device; 3 –Holder; 4 – Mould probe. 
 
Results: Ionization chamber calibration factor ND,w 
=3.042·108 Gy/C. Beam quality factor for Ir-192 kQ =0.994 
was found by interpolation. Decay factor is 1.76. Reading: 
787 pC/min. Correction kT,P =1.022. Result for dose rate: 
0.428 Gy/min. Source-to-chamber distance is 42.02 mm 
(summation of: 39.54 mm - positioning device length; 0.05 
mm – device correction; 3.43 mm - chamber radius; -1.0 mm 
source-to-catheter upper surface distance; 0.05 mm - 
chamber dimentional correction). At the source-chamber 
distance 42.02 mm the TPS gives dose rate 0.434 Gy/min (or 
difference with measurements 1.4%). Taking into account 
absolute calibration of the source activity correction (-1%) by 
well-chamber, final difference reduces to 0.4%. 
 
Conclusion: Proposed simple design of radiation source 
holder with ionization chamber positioning device 
demonstrated agreement (within 1%) measured-to-TPS values 
for dose rate at the distance ~ 4 cm.  
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Purpose or Objective: This study was conducted for the 
purpose of establishing a quality assurance (QA) system for 
brachytherapy that can ensure patient-specific QA by 
enhancing dosimetric accuracy for patient therapy plan. The 
patient-specific QA is designed to measure point absorbed 
dose and 2D dose distribution for patient therapy plan 
 
Material and Methods: We fabricated a solid phantom that 
allowed for the insertion of an applicator for patient-specific 
QA and used an ion chamber and a film as measuring devices. 
The patient treatment plan were exported to the QA dose 
calculation software, which calculated the time weight of 
dwell position stored in the plan DICOM(Digital Imaging and 
Communications in Medicine) file to obtain an overall beam 
quality correction factor and apply this correction to dose 
calculations. Experiments were conducted after importing 
the patient treatment planning source data for the fabricated 
phantom and inserting the applicator, ion chamber, and film 
into the phantom. On completion of dose delivery, the doses 
to the ion chamber and film were checked against the 
corresponding treatment plan to evaluate the dosimetric 
accuracy. For experimental purposes, five treatment plans 
were randomly selected. 
 
Results: The beam quality correction factors for ovoid and 
tandem were found to be 1.15 and 1.10–1.12, respectively. 
The beam quality correction factor in tandem fluctuated by 
approximately 2%, depending on changes in the dwell 
position. Doses measured using the ion chamber showed 
differences ranging from -2.4% to 0.6%, as compared to the 
planned doses. As for the film, the passing rate was 90% or 
higher when assessed using the gamma value of local dose 
difference at 3% and Distance to agreement at 3 mm. 
 
Conclusion: This study intended to establish a QA system for 
the purpose of enhancing the dosimetric accuracy of 
treatment planning for high-dose-rate brachytherapy. 
Experiments and assessments related to patient-specific QA 
were implemented as planned. As a result, the self-
fabricated phantom was found to be suitable for QA in 
clinical settings. The proposed patient-specific QA for 
treatment planning is expected to contribute to reducing 
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Purpose or Objective: In Poland, there are 32 centres 
performing brachytherapy, which treated 10948 patients in 
2014. In total, all these centres use about 50 HDR machines 
with Ir-192 sources. Each source has to be replaced every 
three months, and the new sources have to be calibrated. In 
every centre this is done by measuring the source output with 
a well ionization chamber. Each centre has at least one such 
chamber which in turn has to be calibrated against the 
secondary standard. The Polish Secondary Standard 
Dosimetry Laboratory offers such calibrations for which it is 
accredited by the Polish Centre for Accreditation. The SSDL 
in Warsaw is the only laboratory in Poland and in central and 
eastern Europe performing calibration of such type of 
chambers. The service started in 2012 and since then 36 
calibrations have been performed. In this presentation the 
calibration results are analyzed. 
 
Material and Methods: The calibration procedure for well 
chambers was established at the SSDL in 2012. As a secondary 
standard, a PTW well chamber type TW33004 has been used.. 
At the Polish SSDL, the extended uncertainty of the 
calibration coefficient for user's chambers is 2.8% (k=2). The 
calibrations are performed using the Ir-192 source of the 
MicroSelectron HDR unit. Until May 2015 the SSDL calibrated 
30 well chambers from the following manufacturers: 
